Linked from

The 178 pages that link to Pharmacokinetics, each with the reason it gives.

• CarboplatinNarrower topic: Carboplatin dosing depends strongly on how quickly the kidneys clear it from the blood.

• ClonazepamNarrower topic: Clonazepam’s long elimination half-life helps explain its duration and potential accumulation.

• DiltiazemNarrower topic: Formulation and metabolism shape how diltiazem dosing is scheduled.

• LisinoprilNarrower topic: Lisinopril’s oral absorption and renal elimination shape its dosing and accumulation risks.

• EnalaprilNarrower topic: Its absorption and conversion shape enalapril’s dosing and duration of action.

• EscitalopramNarrower topic: These processes shape escitalopram's dosing interval and interactions.

• PseudoephedrineNarrower topic: Absorption and elimination help explain pseudoephedrine’s onset and duration.

• TadalafilNarrower topic: Tadalafil’s long duration is explained by its absorption and elimination profile.

• TobramycinNarrower topic: Tobramycin's dosing depends on its distribution, renal elimination, and concentration-dependent activity.

• DimethyltryptamineNarrower topic: DMT’s onset and duration vary sharply with administration route and metabolism.

• HydralazineNarrower topic: Hydralazine’s metabolism and variable exposure shape its dosing and duration of effect.

• PhenoxymethylpenicillinNarrower topic: Absorption and elimination help determine penicillin V's oral dosing schedule.

• PhenytoinNarrower topic: Phenytoin's nonlinear metabolism makes small dose changes produce unexpectedly large concentration shifts.

• SalmeterolNarrower topic: These processes help determine salmeterol's dosing interval and systemic exposure.

• GlibenclamideNarrower topic: Its principles explain glibenclamide’s duration, metabolism, and dosing considerations.

• IndometacinNarrower topic: These processes determine indometacin’s dosing intervals and how long its effects persist.

• Pharmaceutical preparationsNarrower topic: Preparation design influences the drug’s movement through the body.

• PiroxicamNarrower topic: Piroxicam’s unusually long elimination half-life shapes its dosing and persistence after treatment stops.

• Therapeutic antibodyNarrower topic: Antibody size, recycling, and target binding produce distinctive concentration profiles.